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The rare neurological disorders frontotemporal
dementia and British dementia have been linked to two
mutant genes whose products constitute the fibrils that
define the two disease pathologies. Two recent studies
add to the mounting circumstantial case that protein
fibrillization, inside (neurofibrillary tangles) or outside
(amyloid plaques) of the neuron, may be pathogenic
and suggest that either or both of these mechanisms
could initiate Alzheimer’s disease.
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Introduction 
Modern criteria to diagnose Alzheimer’s disease (AD)
require the presence of extracellular amyloid plaques and
intracellular neurofibrillary tangles (NFTs) in the clinical
setting of dementia. As a deeper understanding of the com-
position and generation of these pathological entities
emerged, a fierce debate developed concerning where these
two very distinct entities are positioned in the AD patho-
genic cascade. Further complicating the debate is a group of
patients with neurodegenerative conditions that overlap
clinically and pathologically with AD, but show a surprising
variety of confounding lesions. Perhaps most common are
those conditions with Lewy bodies that affect as many as
10–20% of patients who are clinically diagnosed with ‘prob-
able AD’. Lewy bodies are intracellular fibrillar deposits
that typically contain the protein α-synuclein and often also
contain additional abundant cytoplasmic proteins, including
ubiquitin. They occur either in combination with extracel-
lular amyloid plaques (Alzheimer’s disease–Lewy body
variant, AD–LBV; see Table 1) or alone (diffuse Lewy body
disease; DLBD). To what extent these disorders represent
variants of AD and at what point they diverge from the
pathway that leads to classical AD can only be resolved by
applying the tools of molecular genetics (to identify disease-
linked mutations, determine disease-associated patterns of
gene expression and construct gene-targeted animal
models), cell biology (to determine the link between
protein fibrillization and neuronal death) and protein chem-
istry (to characterize the responsible proteins and to find
drug-like molecules to alter their behavior in vivo). 
The earliest genetic information, now almost ten years
old, strongly implicates the formation of extracellular
amyloid plaque as a key process in the pathogenesis of
AD. Although most cases of late-onset AD are sporadic,
rare early-onset forms of AD (FAD) carry mutations that
generally influence the production of Aβ, the major
plaque protein [1]. This discovery focused attention on
the fibrillization of Aβ as a key upstream event in AD
pathogenesis. The ultimate test of this proposal will
depend on studies of compounds that inhibit specific
steps in the generation, assembly and deposition of Aβ. In
order to test the effects of such compounds, it is critical to
produce animal models with AD-like symptoms, in addi-
tion to AD-like pathology. Without such models we can
only rely on the accumulation of circumstantial evidence
regarding the role of the various fibrillar deposits.
Because other neurodegenerative diseases share many of
the properties of AD [2], particularly with regard to the self-
assembly of proteins into pathological aggregates, it is
timely to discuss here two such rare diseases with recent
insights that may apply to this entire category of diseases.
These diseases are frontotemporal dementia (FTD) and
British dementia (FBD), for which causative mutations
have been identified and biochemical information is begin-
ning to emerge. FTD is characterized by intracellular accu-
mulations of hyperphosphorylated tau isoforms that form a
variety of inclusions, including, but not limited to, classical
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Table 1
Dementias characterized by fibrillar protein deposits.
Familial Intracellular Extracellular
disease protein pathology protein pathology Gene/protein
FAD NFTs and Aβ amyloid APP/Aβ
Lewy bodies plaques
FTD NFTs and other None Tau/tau
tau inclusions
FBD NFTs ABri amyloid BRI/ABri
plaques
Sporadic Intracellular Extracellular Fibrillar
disease protein pathology protein pathology proteins
AD NFTs Aβ amyloid Tau and Aβ
plaques
AD–LBV Lewy bodies Aβ amyloid α-Synuclein
plaques and Aβ
DLBD Lewy bodies None α-Synuclein
FAD, familial Alzheimer’s disease; FTD, frontotemporal dementia; FBD,
British dementia.
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AD NFTs. About 14 different mutations in the tau gene
are responsible for about half of the cases clinically grouped
under the term FTD (reviewed in [3]; see Figure 1). In
contrast, FBD is characterized by both extracellular
amyloid plaques (albeit of a different protein composition
than those in AD) and NFTs. FBD is caused by a mutation
in the gene encoding the major plaque protein [4]. 
Frontotemporal dementia and mutations in the tau gene
The recent discovery of mutations in the tau gene that
lead to the complex phenotypes collected under the clini-
cal term fronto-temporal dementia (FTD) have pointed
squarely at sites in tau that can lead to the intracellular
accumulation of tau aggregates. Although these diseases
are quite rare, the presence of intracellular tau aggregates,
called neurofibrillary tangles, in AD suggests that a deeper
understanding of how the tau protein self-assembles into
abnormal filaments may have broader ramifications. In
AD, tau assumes a characteristic ultrastructural appear-
ance in which two filaments, each about 15 nm thick, heli-
cally wind around each other with a periodicity of
70–80 nm (Figure 2). This is not the only configuration
found among tau aggregates in either AD or in FTD,
however. Tau can form straight filaments or even diffuse
intracellular free tau that is no longer found in its normal
intracellular location, in association with microtubules.
The one common denominator found in all tau inclusions
is the presence of a hyperphosphorylated form of tau
detectable with a variety of antibodies directed against
specific phosphorylation sites. The origin of the hyper-
phosphorylated state of tau probably sits at or near the
enigmatic center of the neurodegenerative disease
process. One of the more intriguing ideas about the
observed hyperphosphorylation of tau is that it represents
the activation of a mitotic program in a cell (the neuron),
which is irreversibly post-mitotic.
Tau is a substrate of the prolyl isomerase Pin1
Amide bonds involving the proline secondary amino group
populate both cis and trans configurations and the intercon-
version between the two is often a slow step in protein
folding. Consequently, prolyl isomerase enzymes exist that
catalyze this reaction, possibly by a nucleophilic mecha-
nism. The prolyl isomerase Pin1 isomerizes Ser–Pro or
Thr–Pro bonds and therefore serves as a highly conserved
and essential regulator of mitotic phosphoproteins [5–8].
The recent discovery that Pin1 may significantly contribute
to the dysfunction of tau and the neurofibrillary tangle of
AD provides an intriguing novel target [9]. The paper by
Lu and colleagues [9] reports that Pin1 is depleted from the
soluble fraction of brain and accumulates in the insoluble
fraction, where it binds to the tau protein in the neurofibril-
lary tangles. Through its WW domain, Pin1 also showed
specific and high-affinity binding to one tau peptide con-
taining pThr231, one of the several sites on tau phosphory-
lated in AD brain. How the other tau phosphorylation sites
in the Alzheimer brain might be affected by Pin1 activity is
unknown. Interestingly, regarding the curious relationship
to mitotic activation, this site is readily phosphorylated in
vitro by cdc2 [10–12]. When tau is phosphorylated by cdc2
in vitro, its ability to bind and polymerize microtubules is
reduced, an effect that can be reversed by incubation with
Pin1. This key observation suggests that isomerization of
a proline amide permits tau to bind to microtubules in the
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Figure 1
Human tau sequence. One signature of the repeated sequences in the
microtubule-binding domain is PGGG, which is underlined. Residues
that are mutated in FTD are in bold. 
Figure 2
Atomic force microscopy images of
brain-derived tau, in the form of paired helical
filaments (PHFs). The helical periodicity of
70 nm is clearly visible in both images. These
fibrils resemble amyloid fibrils produced in
vitro from synthetic Aβ (helical periodicity of
~40nm). Images are 1.25 µm (left panel) and
1.5 µm (right panel) square. PHFs were
isolated by Lisa Flanagan and imaged by
James Harper.
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presence of a phosphate group that is otherwise inhibitory
towards binding. In attempting to relate the finding to the
disease, the authors suggest that tau hyperphosphoryla-
tion may create a number of binding sites that exceeds
the availability of Pin1. Alternatively, the sequestration of
Pin1 in AD brain depletes soluble Pin1, which may lead
to apoptosis [5]. 
Familial British dementia and mutations in the gene BRI 
FBD is an autosomal dominant disorder of undetermined
etiology. It appears to be a rare disease, but its clinical,
genetic and pathological analysis has been facilitated by
the existence of a large afflicted family, comprising more
than 200 members and encompassing seven generations.
FBD, like FAD and FTD, is a late-onset progressive
dementia, but patients also exhibit other features associ-
ated with cerebellar involvement, such as spasticity and
ataxia (balance problems). The FBD brain is characterized
by amyloid plaques in the hippocampus and cerebellum,
amyloid deposits in the vasculature, and, like FAD and
FTD, cytoplasmic neurofibrillary tangles that resemble
those characteristic of AD [13].
Although the FBD pathology resembles some types of FAD
and prion disease, no staining of brain sections for Aβ or the
prion protein could be demonstrated using immunohisto-
chemical methods [14]. The identity of the FBD amyloid
plaque protein was therefore unknown. A recent break-
through paper describes the identification, using biochemi-
cal methods, of this protein and the subsequent discovery of
the genetic basis for this rare disorder [4]. Using an approach
similar to that which allowed George Glenner and cowork-
ers [15] to identify Aβ as the major AD amyloid protein, the
New York group [4] was able to purify an ~4 kDa peptide
(designated ABri). Using partial sequence information from
purified tryptic fragments, a previously uncharacterized
gene on chromosome 13 was identified that encodes a 266
residue protein, designated the ABri precursor protein
(Figure 3). Interestingly, the tryptic peptide derived from
the ABri carboxyl terminus was perfectly homologous to a
sequence to the 3′ side of the first stop codon and immedi-
ately before the next in-frame stop codon. This portion of
the wild-type gene would not be expected to be translated.
Once the ABri precursor gene had been sequenced, the
affected family members were analyzed in order to deter-
mine the molecular basis for FBD. Seven affected individ-
uals had a single nucleotide transition in stop codon 267,
which resulted in its replacement with an arginine residue.
This change would allow translation to continue to the
next stop codon, resulting in the addition of 11 residues at
the protein carboxyl terminus (Figure 3). All the unaf-
fected kindred retained the stop codon, as did 42 unre-
lated individuals with unrelated neurologic disorders and
72 normal individuals of comparable ethnicity (the stop
codon was also conserved in the mouse sequence).
Finally, antibodies generated against brain-derived FBD
amyloid as well as synthetic fragments of ABri stained
amyloid plaques in brain tissue sections from FBD
patients, but not plaques from AD patients or patients
with several other brain and systemic amyloidoses. 
The ABri precursor protein is widely expressed in brain,
as well as several peripheral tissues, such as the placenta,
kidney and pancreas. Sequence analysis suggests that the
ABri precursor has a single membrane-spanning segment
(residues 52–74, Figure 3) and, furthermore, suggests
that it is a ‘type II’ integral membrane protein, in which
the short amino-terminal segment is located on the cyto-
plasmic face of the membrane. This topology has yet to be
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Figure 3
A cartoon depiction of several possible
scenarios to explain the pathogenicity of the
FBD mutation. The known aspects are shown
in color. These include the sequence of the
ABri peptide and its relationship to the wild-
type and mutant precursor sequences. (Note
the carboxy-terminal extension of the mutant
precursor in red.) It is also clear that the ABri
peptide is cleaved from mutant precursor and
that this peptide fibrillizes in vivo (solid
arrows). In contrast, it is unknown whether
the truncated version of ABri, derived from
the wild-type precursor, is amyloidogenic or,
in fact, whether it is released by proteolysis
in the first place (see text). In addition, the
putative transmembrane region has not been
experimentally verified, nor has the
orientation of the wild-type and mutant
proteins [4]. See the note added in proof
for a recent development.
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confirmed (J. Ghiso, personal communication) and is
suspect, because no signal sequence for insertion into the
endoplasmic reticulum (ER) membrane was detected.
The ABri sequence (Figure 3) is not homologous to any
known amyloid proteins, which is not unexpected,
because none of this group is homologous, despite the fact
that they all form amyloid fibrils of similar morphology.
The amino acid composition of ABri is unremarkable and
offers no clues as to its amyloidogenicity. Several scenarios
regarding the precursor-to-ABri conversion can be envi-
sioned (Figure 3). First, the carboxy-terminal extension
may create a cleavage site in the precursor that releases
ABri into the extracellular space/ER/vesicle or into the
cytoplasm, depending on the topology of the precursor. It
seems unlikely, however, that the extension would create
a new proteolytic site 24 residues upstream. Alternatively,
both the wild-type and mutant precursors may be cleaved
but the wild-type cleavage product may be soluble and
easily degraded, in contrast to ABri, which is fibrillogenic.
Finally, it is possible, but without precedent, that the
carboxy-terminal extension could reverse the topology of
the ABri precursor, leading to intracellular release of a fib-
rillogenic peptide (after cell death and lysis, plaques could
end up extracellular). The observation that FBD amyloid
contains fragments of a normally cytoplasmic protein,
tubulin [16], may prove to be important in distinguishing
between these scenarios and in determining the mecha-
nism of ABri neurotoxicity.
Conclusions
FTD and FBD clearly constitute two more examples of
neurodegenerative diseases that are characterized by fibril-
lar deposits and are autosomal dominantly inherited via
point mutations in the genes encoding proteins that
undergo fibrillization in these diseases. This list includes
early-onset AD, early-onset Parkinson’s disease and Hunt-
ington’s disease [2]. It remains to be determined whether
these diseases share an underlying neurotoxic mechanism
and whether they may be treated using similar therapeutic
strategies. It is clear that, as these diseases are more closely
analyzed, disease-specific targets for therapeutic interven-
tion, such as the PPI enzyme discussed above, will emerge. 
Note added in proof
Some of the questions posed in Figure 3 are addressed in a
recent study of the topology and metabolism of the prod-
ucts of the FBD gene (termed BRI-L by these authors,
referred to as ABri precursor above) and its normal relative
(BRI) (Kim, S.-H., et al., & Sisodia, S.S. (1999). Furin medi-
ates enhanced production of fibrillogenic ABri peptides in
familial British dementia. Nat. Neurosci. 2, 984-988). A
variant of BRI in which both termini were ligated to
epitope tags was expressed in mouse neuroblastoma cells.
The predominant topology of the chimeric protein was
demonstrated to be that predicted by Ghiso and coworkers
[4] with the amino-terminal sequence in the cytoplasm.
The mutant protein, BRI-L, was not analyzed by this
method. However, the ‘type II’ topology of the mutant was
supported by the fact that cultured cells transfected with
either mutant or wild-type constructs secreted the
expected carboxy-terminal cleavage products. Processing
depended on the subtilisin-like protease furin. In the case
of the mutant BRI construct, the amount of secreted
peptide was increased relative to the wild-type construct.
Finally, synthetic peptides corresponding to the carboxy-
terminal sequences were shown to have different proper-
ties; under conditions where the peptide based on
wild-type BRI was soluble, the ABri peptide formed small
oligomeric structures that are not amyloid fibrils, but
resemble the Aβ protofibril, a fibril precursor that has been
extensively characterized by one of us (Harper, J.D., Wong,
S.S., Lieber, C.M. & Lansbury, P.T. (1999). Assembly of
an Aβ protofibril: an in vitro model for a possible early
event in Alzheimer’s disease. Biochemistry 38, 8972-8890).
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